Technical Analysis for EBS - Emergent Biosolutions, Inc.

Grade Last Price % Change Price Change
D 9.11 -3.39% -0.32
EBS closed down 3.39 percent on Thursday, December 5, 2024, on 13 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.
5 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down

Date Alert Name Type % Chg
Fell Below 50 DMA Bearish 0.00%
180 Bearish Setup Bearish Swing Setup 0.00%
NR7 Range Contraction 0.00%
NR7-2 Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
50 DMA Support Bullish -3.39%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -3.39%
NR7 Range Contraction -3.39%
Narrow Range Bar Range Contraction -3.39%

   Recent Intraday Alerts

Alert Time
Possible NR7 about 4 hours ago
Fell Below Previous Day's Low about 7 hours ago
Down 3% about 7 hours ago
60 Minute Opening Range Breakdown about 8 hours ago
Fell Below 50 DMA about 8 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Emergent Biosolutions, Inc. Description

Emergent BioSolutions, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and commercialization of specialized products for use in defense and commercial markets in the United States and internationally. The company operates in two segments, Biodefense and Biosciences. It markets BioThrax, an FDA licensed vaccine for the prevention of anthrax disease; and RSDL (decontamination lotion) product for removal or neutralization of chemical warfare agents from the skin. The company's development pipeline includes Anthrivig (Human Anthrax Immunoglobulin), a polyclonal anthrax therapeutic candidate; PreviThrax, a recombinant anthrax vaccine candidate, NuThrax (Anthrax Vaccine Adsorbed with CPG 7909 Adjuvant); BioThrax with a novel adjuvant; and Thravixa (Fully Human Anthrax Monoclonal Antibody), a therapeutic being studied for use against symptomatic anthrax infection. In addition, it develops TRU-016, a humanized anti-CD37 therapeutic candidate, based on its ADAPTIR (Modular Protein Technology) platform that is in Phase I/II clinical trials to treat chronic lymphocytic leukemia. Further, the company develops preclinical product candidates targeted for solid tumors, inflammatory bowel disease, graft versus host disease, rheumatoid arthritis, and a human vaccine to protect against influenza caused by a range of circulating H5 influenza strains. Emergent BioSolutions, Inc. was founded in 1998 and is headquartered in Rockville, Maryland.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Pharmaceutical Solid Tumors Drugs Monoclonal Antibody FDA Influenza Vaccines Rheumatoid Arthritis Inflammatory Bowel Disease Vaccination Lotion Blood Plasma Chronic Lymphocytic Leukemia Lymphocytic Leukemia Decontamination Specialized Products Biodefense Host Disease Biological Warfare Graft Versus Host Disease Monkeypox Anthrax Chemical Warfare Poxviruses Anthrax Vaccines Chemical Warfare Agents Naloxone

Is EBS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 15.1
52 Week Low 1.42
Average Volume 1,525,211
200-Day Moving Average 6.83
50-Day Moving Average 9.29
20-Day Moving Average 9.75
10-Day Moving Average 9.67
Average True Range 0.72
RSI (14) 46.81
ADX 17.62
+DI 26.34
-DI 26.18
Chandelier Exit (Long, 3 ATRs) 10.58
Chandelier Exit (Short, 3 ATRs) 9.86
Upper Bollinger Bands 11.84
Lower Bollinger Band 7.66
Percent B (%b) 0.35
BandWidth 42.85
MACD Line 0.05
MACD Signal Line 0.11
MACD Histogram -0.0598
Fundamentals Value
Market Cap 472.67 Million
Num Shares 51.9 Million
EPS -15.56
Price-to-Earnings (P/E) Ratio -0.59
Price-to-Sales 0.08
Price-to-Book 0.12
PEG Ratio 1.55
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 9.63
Resistance 3 (R3) 9.67 9.54 9.54
Resistance 2 (R2) 9.54 9.40 9.52 9.52
Resistance 1 (R1) 9.32 9.32 9.26 9.28 9.49
Pivot Point 9.19 9.19 9.15 9.17 9.19
Support 1 (S1) 8.97 9.05 8.91 8.94 8.73
Support 2 (S2) 8.84 8.97 8.82 8.70
Support 3 (S3) 8.63 8.84 8.68
Support 4 (S4) 8.59